Swedish Orphan Biovitrum AB Sweden

Sobi and Sanofi's Foundation S extend partnership with the World Federation of Hemophilia Humanitarian Aid Program

Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistance
Evan Berland | [phone] | [e-mail]
Nicolas Obrist | [phone] | [e-mail]
Victor Rouault | [phone] | [e-mail]
Léo Le Bourhis | [phone] | [e-mail]
Timothy Gilbert | [phone] | [e-mail]

About Sobi 

Sobi® is a global biopharma company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.  

Contacts 

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-and-sanofi-s-foundation-s-extend-partnership-with-the-world-federation-of-hemophilia-humanitari,c4140181

The following files are available for download:

https://mb.cision.com/Main/14266/4140181/3409015.pdf

Sobi and Sanofi extend their partnership with WFH Humanitarian Program

 

View original content:https://www.prnewswire.co.uk/news-releases/sobi-and-sanofis-foundation-s-extend-partnership-with-the-world-federation-of-hemophilia-humanitarian-aid-program-302438102.html